Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
CABOSUN II trial: what clinicians have said so far
Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma
- NCT03541902 ↗
- Active, not recruiting
- M.D. Anderson Cancer Center
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on CABOSUN II yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on CABOSUN II so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built |
The trial
ClinicalTrials.gov- Official title
- Cabosun Ii: Cabozantinib Versus Sunitinib for Metastatic Variant Histology Renal Cell Carcinoma
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Malignant Neoplasms of Urinary Tract; Renal Cell Carcinoma; Chromophobe Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma; Papillary Renal Cell Carcinoma; Renal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3 Gene Fusions; Sarcomatoid Renal Cell Carcinoma; Stage IV Renal Cell Cancer AJCC v8; Unclassified Renal Cell Carcinoma
- Interventions
- Cabozantinib; Sunitinib Malate
- Arms
- Group 1 (cabozantinib) · Experimental
- Group 2 (sunitinib malate) · Experimental
- Enrollment
- 32
- Primary outcomes
- Progression-Free Survival (PFS) Evaluated Using RECIST 1.1 Criteria
- Sponsor
- M.D. Anderson Cancer Center with Exelixis, National Cancer Institute (NCI)
- Start
- May 15, 2018
- Primary completion
- Jul 31, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT03541902 · updated Jul 16, 2026